

REFERENCE

REFERENCE

- [1] Graham, S., Masese, L., Gitau, R., Jalalian-Lechak, Z., Richardson, B., Peshu, N., et al. (2010). Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. **J Infect Dis**, 202(10), 1538-1542.
- [2] Wahl, L. and Nowak, M. (2000). Adherence and drug resistance: predictions for therapy outcome. **Proc Biol Sci**, 267(1445), 835-843.
- [3] Sethi, A., Celentano, D., Gange, S., Moore, R. and Gallant, J. (2003). Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. **Clin Infect Dis**, 37(8), 1112-1118.
- [4] Cressey, T. and Lallemand, M. (2007). Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. **Infect Genet Evol**, 7(2), 333-342.
- [5] Domingo, P., Cabeza Mdel, C., Torres, F., Salazar, J., Gutierrez Mde, IM., Mateo, M., et al. (2013). Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. **PLoS One**, 8(2), e57347.
- [6] Martin, A.M., Nolan, D., Gaudieri, S., Almeida, C.A., Nolan, R., James, I., et al. (2004). Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. **Proc Natl Acad Sci U S A**, 101(12), 4180-4185.
- [7] Guaraldi, G., Stentarelli, C., Zona, S. and Santoro, A. (2013). HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy. **Drugs**, 73(13), 1431-1450.
- [8] Núñez, M. (2006). Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. **J Hepatol**, 44(1 Suppl), S132-139.
- [9] Pirmohamed, M. (2009). Clinical management of HIV-associated lipodystrophy. **Curr Opin Lipidol**, 20(4), 309-314.

- [10] Pirmohamed, M., Drummond, N., Naisbitt, D. and Park, B. (2007). Drug hypersensitivity reactions in patients with HIV disease. **Expert Rev Clin Immunol**, 3(3), 395-410.
- [11] Kamerman, P., Wadley, A. and Cherry, C. (2012). HIV-associated sensory neuropathy: risk factors and genetics. **Curr Pain Headache Rep**, 16(3), 226-236.
- [12] Phillips, E.J. and Mallal, S.A. (2008). Pharmacogenetics and the potential for the individualization of antiretroviral therapy. **Current Opinion in Infectious Diseases**, 21(1), 16-24.
- [13] Vidal, F., Gutierrez, F., Gutierrez, M., Olona, M., Sanchez, V., Mateo, G., et al. (2010). Pharmacogenetics of adverse effects due to antiretroviral drugs. **AIDS Reviews**, 12(1), 15-30.
- [14] Chung, W., Hung, S. and Chen, Y. (2007). Human leukocyte antigens and drug hypersensitivity. **Current Opinion in Allergy & Clinical Immunology**, 7(4), 317-323.
- [15] Bharadwaj, M., Illing, P. and Kostenko, L. (2010). Personalized medicine for HLA-associated drug-hypersensitivity reactions. **Personalized Medicine**, 7(5), 495-516.
- [16] Kim, S., Ye, Y., Palikhe, N.S., Kim, J. and Park, H. (2010). Genetic and ethnic risk factors associated with drug hypersensitivity. **Current Opinion in Allergy & Clinical Immunology**, 10(4), 280-290.
- [17] Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., et al. (2006). Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. **Pharmacogenetics and Genomics**, 16, 297-306.
- [18] Lochareonkul, C., Loplumlert, J., Limotai, C., Wiwat, K., Desudchit, T., Tongkobpetch, S., et al. (2008). Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. **Epilepsia**, 49(12), 2087-2091.
- [19] Chang, C.-C., Too, C., Murad, S. and Hussein, S. (2011). Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. **Int J Dermatol**, 50(2), 221-224.

- [20] Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M. and Tassaneeyakul, W. (2013). Relationship Between the HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. **JAMA Dermatol**, 149(9), 1025-1032.
- [21] Somkrua, R., Eickman, E., Saokaew, S., Lohitnavy, M. and Chaiyakunapruk, N. (2011). Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. **BMC Med Genet**, 12, 118.
- [22] Alfirevic, A. and Pirmohamed, M. (2010). Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. **Pharmacogenomics**, 11(4), 497-499.
- [23] Wangsomboonsiri, W., Mahasirimongkol, S., Chantarangsu, S., Kiertiburanakul, S., Charoenyingwattana, A., Komindr, S., et al. (2010). Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. **Clin Infect Dis**, 50(4), 597-604.
- [24] Chantarangsu, S., Mushiroda, T., Mahasirimongkol, S., Kiertiburanakul, S., Sungkanuparph, S., Manosuthi, W., et al. (2009). HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. **Pharmacogenet Genomics**, 19(2), 139-146.
- [25] Carr, D., Chaponda, M., Jorgensen, A., Castro, E., van Oosterhout, J., Khoo, S., et al. (2013). Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. **Clin Infect Dis**, 56(9), 1330-1339.
- [26] Martin, M.A., Klein, T.E., Dong, B.J., Pirmohamed, M., Haas, D.W. and Kroetz, D.L. (2012). Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. **Clinical Pharmacology and Therapeutics**, 91(4), 734-738.

- [27] Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. **Lancet**, 359(9308), 727-732.
- [28] Hughes, A.R., Mosteller, M., Bansal, A.T., Davies, K., Haneline, S.A., Lai, E.H., et al. (2004). Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. **Pharmacogenomics**, 5(2), 203-211.
- [29] Munderi, P., Snowden, W.B., Walker, A.S., Kityo, C., Mosteller, M., Kabuye, G., et al. (2011). Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. **Trop Med Int Health**, 16(2), 200-204.
- [30] Sun, H.Y., Hung, C.C., Lin, P.H., Chang, S.F., Yang, C.Y., Chang, S.Y., et al. (2007). Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. **J Antimicrob Chemother**, 60(3), 599-604.
- [31] Mallal, S., Phillips, E., Carosi, G., Molina, J.M., Workman, C., Tomazic, J., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. **N Engl J Med**, 358(6), 568-579.
- [32] Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., et al. (2008). High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. **Clin Infect Dis**, 46(7), 1111-1118.
- [33] Hetherington, S., Hughes, A.R., Mosteller, M., Shortino, D., Baker, K.L., Spreen, W., et al. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. **Lancet**, 359(9312), 1121-1122.
- [34] Gallo, R.C. (2006). A reflection on HIV/AIDS research after 25 years. **Retrovirology**, 3(72), 1-7.
- [35] Piot, P. and Quinn, T. (2013). Response to the AIDS pandemic--a global health model. **N Engl J Med**, 268(23), 2210-2218.
- [36] Pavlos, R. and Phillips, E.J. (2012). Individualization of antiretroviral therapy. **Pharmgenomics Pers Med**, 5, 1-17.

- [37] Gazzard, B. (2005). Antiretroviral therapy for HIV: medical miracles do happen. **Lancet**, 366(9483), 346-347.
- [38] World Health Organization. (2010). **Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision**. Retrieved April 13, 2014, from <http://www.who.int/hiv/pub/arv/adult2010/en/>
- [39] Somnuek, S., Wichai, T., Chitlada, U., Sanchai, C., Sorakij, B., Manoon, L., et al. (2010). Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. **Asian Biomedicine**, 4(4), 515-528.
- [40] Glaxo Wellcome. (2012). **Product Information: Ziagen®, abacavir sulfate tablets and oral solution**. Retrieved April 11, 2014, from https://hivdb.stanford.edu/pages/linksPages/ABC_NRTI.pdf
- [41] Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., et al. (2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. **Clin Ther**, 23(10), 1603-1614.
- [42] Boehringer Ingelheim Pharmaceuticals Inc. (2014). **Product Information: Viramune® tablets and oral suspension**. Retrieved April 11, 2014, from <http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf>
- [43] Yuan, J., Guo, S., Hall, D., Cammett, A., Jayadev, S., Distel, M., et al. (2011). Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian and European descent. **AIDS**, 25(10), 1271-1280.
- [44] Bristol-Myers Squibb Company. (2012). **Product Information: ZERIT® (stavudine) capsules and oral solution**. Retrieved April 14, 2014, from http://packageinserts.bms.com/pi/pi_zerit.pdf
- [45] อรวดี หาญวิวัฒน์วงศ์. (2551). **วิทยาภูมิคุ้มกันพื้นฐานและคลินิก : Basic and Clinical Immunology (พิมพ์ครั้งที่ 2)**. กรุงเทพฯ: คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย.

- [46] Abbas, A. and Lichtman, A. (2006). **Basic Immunology: Functions and Disorders of the Immune System** (2nd.). Philadelphia: Elsevier.
- [47] Johnson, J. and Bootman, J. (1995). Drug-related morbidity and mortality. A cost-of-illness model. **Arch Intern Med**, 155(18), 1949-1956.
- [48] Pichler, W. (2003). Delayed drug hypersensitivity reactions. **Ann Intern Med**, 139(8), 683-693.
- [49] Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., et al. (2011). Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. **Hum Mol Genet**, 20(5), 1034-1041.
- [50] Pichler, W., Adam, J., Daubner, B., Gentinetta, T., Keller, M. and Yerly, D. (2010). Drug hypersensitivity reactions: pathomechanism and clinical symptoms. **Med Clin North Am**, 94(4), 645-664.
- [51] Watkins, S. and Pichler, W. (2013). Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRV β 20-1, altering pHLA recognition. **PLoS One**, 8(10), e76211.
- [52] Wei, C., Chng, W., Huang, H., Chen, Y. and Hung, S. (2012). Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. **J Allergy Clin Immunol**, 129(6), 1562-1569.
- [53] Lee, H. and Chung, W. (2013 Aug). Toxic epidermal necrolysis: the year in review. **Curr Opin Allergy Clin Immunol**, 13(4), 330-336.
- [54] Illing, P., Vivian, J., Dudek, N., Kostenko, L., Chen, Z., Bharadwaj, M., et al. (2012). Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. **Nature**, 486(7404), 554-558.
- [55] Adam, J., Wullemmin, N., Watkins, S., Jamin, H., Eriksson, K., Villiger, P., et al. (2014). Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses. **PLoS One**, 9(4), e95339.
- [56] Illing, P., Vivian, J., Purcell, A., Rossjohn, J. and McCluskey, J. (2013). Human leukocyte antigen-associated drug hypersensitivity. **Curr Opin Immunol**, 25(1), 81-89.

- [57] Wells, G., Shea, B., O'Connell, D., P., J., Welch, V. and Losos, M.
The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Retrieved April 16, 2014, from http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
- [58] The Cochrane Collaboration. (March 2011). **Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.** Retrieved April 16, 2014, from www.cochrane-handbook.org.
- [59] Downs, S. and Black, N. (1998). The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. **J Epidemiol Community Health**, 52(6), 377-384.
- [60] DerSimonian, R. and Laird, N. (1986). Meta-analysis in clinical trials. **Control Clin Trials**, 7(3), 177-188.
- [61] Higgins, J. and Thompson, S. (2002). Quantifying heterogeneity in a meta-analysis. **Stat Med**, 21(11), 1539-1558.
- [62] Higgins, J., Thompson, S., Deeks, J. and Altman, D. (2003). Measuring inconsistency in meta-analyses. **BMJ**, 327(7414), 557-560.
- [63] Begg, C. and Berlin, J. (1989). Publication bias and dissemination of clinical research. **J Natl Cancer Inst**, 81(2), 107-115.
- [64] Egger, M. and Smith, G. (1998). Bias in location and selection of studies. **BMJ**, 316(7124), 61-66.
- [65] Duval, S. and Tweedie, R. (2000). A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in Meta-Analysis. **American Statistical Association**, 95(449), 89-98.
- [66] Hughes, D.A., Vilar, F.J., Ward, C.C., Alfirevic, A., Park, B.K. and Pirmohamed, M. (2004). Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. **Pharmacogenetics**, 14(6), 335-342.
- [67] Stekler, J., Maenza, J., Stevens, C., Holte, S., Malhotra, U., McElrath, M.J., et al. (2006). Abacavir hypersensitivity reaction in primary HIV infection. **AIDS**, 20(9), 1269-1274.

- [68] Berka, N., Gill, J.M., Liacini, A., O'Bryan, T. and Khan, F.M. (2012). Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. **Hum Immunol**, 73(2), 164-167.
- [69] Phillips, E.J. (2006). Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?. **Clin Infect Dis**, 43(1), 103-105.
- [70] Phillips, E. and Mallal, S. (2009). Successful translation of pharmacogenetics into the clinic: the abacavir example. **Mol Diagn Ther**, 13(1), 1-9.
- [71] Norcross, M., Luo, S., Lu, L., Boyne, M., Gomarteli, M., Rennels, A., et al. (2012). Abacavir induces loading of novel self-peptides into HLA-B*57:01: an autoimmune model for HLA-associated drug hypersensitivity. **AIDS**, 26(11), F21-29.
- [72] Ostrov, D., Grant, B., Pompeu, Y., Sidney, J., Harndahl, M., Southwood, S., et al. (2012). Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. **Proc Natl Acad Sci U S A**, 109(25), 9959-9964.
- [73] Uetrecht, J. and Naisbitt, D. (2013). Idiosyncratic adverse drug reactions: current concepts. **Pharmacol Rev**, 65(2), 779-808.
- [74] Littera, R., Carcassi, C., Masala, A., Piano, P., Serra, P., Ortu, F., et al. (2006). HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. **AIDS**, 20(12), 1621-1626.
- [75] Gatanaga, H., Yazaki, H., Tanuma, J., Honda, M., Genka, I., Teruya, K., et al. (2007). HLA-Cw8 primarily associated with hypersensitivity to nevirapine. **AIDS**, 21(2), 264-265.
- [76] Vitezica, Z., Milpied, B., Lonjou, C., Borot, N., Ledger, T., Lefebvre, A., et al. (2008). HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. **AIDS**, 19(22), 4.
- [77] Likanonsakul, S., Rattanatham, T., Feangvad, S., Uttayamakul, S., Prasithsirikul, W., Tunthanathip, P., et al. (2009). HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. **AIDS Res Ther**, 6(22).

- [78] Gao, S., Gui, X., Liang, K., Liu, Z., Hu, J. and Dong, B. (2012). HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. **AIDS Res Hum Retroviruses**, 28(6), 540-543.
- [79] Phillips, E., Bartlett, J., Sanne, I., Lederman, M., Hinkle, J., Rousseau, F., et al. (2013). Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. **J Acquir Immune Defic Syndr**, 62(2), e55-57.
- [80] Domingo, P., Mateo, M., Pruvost, A., Torres, F., Salazar, J., Gutierrez, M., et al. (2013). Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40:01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. **PLoS One**, 8(6), e67035.
- [81] Kiertiburanakul, S., Sungkanuparph, S., Charoenyingwattana, A., Mahasirimongkol, S., Sura, T. and Chantratita, W. (2008). Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. **Curr HIV Res**, 6(1), 65-69.
- [82] Carr, A., Law, M. and HIV Lipodystrophy Case Definition Study Group. (2003). An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. **J Acquir Immune Defic Syndr**, 33(5), 571-576.
- [83] Lichtenstein, K., Ward, D., Moorman, A., Delaney, K., Young, B., Palella, F. J., et al. HIV Outpatient Study Investigators. (2001). Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. **AIDS**, 15(11), 1389-1389.
- [84] Allele Frequency Net Database. (2005). **Allele frequencies in worldwide populations**. Retrieved March 25, 2014, from <http://www.allelefreqencies.net>
- [85] Joep J. van, O., Jane, M., Symon, K., Newton, C., Yassin, N., Elizabeth, K., et al. (2012). Stavudine Toxicity in Adult Longer-Term ART Patients in Blantyre, Malawi. **PLoS One**, 7(7), e42029.

- [86] Sang, H. H., Jialun, Z., Suneeta, S., Sasheela, V., Nittaya, P., Yi-Ming A, C., et al. (2011). Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). **Endocr J**, 58(6), 475-84.
- [87] Martin, A., Smith, D., Carr, A., Ringland, C., Amin, J., Emery, S., et al. (2004). Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. **AIDS**, 18(7), 1029-1036.
- [88] Likanonsakul, S., Rattanatham, T., Feangvad, S., Uttayamakul, S., Prasithsirikul, W., Srisopha, S., et al. (2013). Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. **AIDS Res Hum Retroviruses**, 29(1), 142-150.
- [89] Bonnet, E., Bernard, J., Fauvel, J., Massip, P., Ruidavets, J. and Perret, B. (2008). Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. **AIDS Res Hum Retroviruses**, 24(2), 169-171.
- [90] Mayo, O. (2008). A century of Hardy-Weinberg equilibrium. **Twin Res Hum Genet**, 11(3), 249-256.
- [91] Salanti, G., Sanderson, S. and Higgins, J. (2005). Obstacles and opportunities in meta-analysis of genetic association studies. **Genet Med**, 7(1), 13-20.
- [92] Smits, K., Schouten, J., Smits, L., Stelma, F., Nelemans, P. and Prins, M. (2005). A review on the design and reporting of studies on drug-gene interaction. **J Clin Epidemiol**, 58(7), 651-654.
- [93] Thakkestian, A., McElduff, P., D'Este, C., Duffy, D. and Attia, J. (2005). A method for meta-analysis of molecular association studies. **Stat Med**, 24(9), 1291-1306.
- [94] Subbaraman, R., Chaguturu, S., Mayer, K., Flanigan, T. and Kumarasamy, N. (2007). Adverse effects of highly active antiretroviral therapy in developing countries. **Clin Infect Dis**, 45(8), 1093-1101.

- [95] Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J., et al. (1999). A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. **AIDS**, 13(13), 1659-1667.
- [96] Christeff, N., Melchior, J., de Truchis, P., Perronne, C. and Gougeon, M. (2002). Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. **Eur J Clin Invest**, 32(1), 43-50.

BIOGRAPHY

BIOGRAPHY

Name-Surname Wimonchat Tangamornsuksan
Date of Birth May 5, 1987
Place of Birth Phitsanulok, Thailand
Address 460/6 Moo8 Phichaisongchram Road, Phitsanulok, Thailand.
65000

Work Experience

2011 Research assistance in Center of Pharmaceutical Outcomes
Research, Faculty of Pharmaceutical Sciences, Naresuan
University, Phitsanulok, Thailand

Education Background

2005 Pharm.D. (Pharmacy) Naresuan University, Phitsanulok,
Thailand.

Publication

Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M. and
Tassaneeyakul, W. (September 1, 2013). Relationship between the
HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson
Syndrome and Toxic Epidermal Necrolysis: A systematic review and
meta-analysis. **JAMA Dermatol**, 149(9), 1025-1032.

FOOTNOTE

- 1 Stavudine (d4T) is relatively inexpensive and is currently a component of first-line therapy in many countries.
- 2 Recommend in who cannot tolerate nevirapine or efavirine